SELLAS Life Sciences (SLS) Depreciation & Amortization (CF) (2010 - 2017)
SELLAS Life Sciences (SLS) reported Depreciation & Amortization (CF) of $25000.0 for Q3 2017, down 16.67% year-over-year from $30000.0 in Q3 2016, and little changed on a QoQ basis from $25000.0 in Q2 2017.
SELLAS Life Sciences (SLS) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $25000.0 in Q3 2017.
- Quarterly Depreciation & Amortization (CF) fell 16.67% year-over-year to $25000.0 in Q3 2017, while the trailing twelve-month figure through Jun 2018 was $25000.0 (up 327.27% YoY) and the FY2016 annual result came in at $3000.0, down 97.2% from the prior year.
- Depreciation & Amortization (CF) held at $25000.0 in Q3 2017 per SLS's latest filing, from $25000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $232000.0 in Q1 2014 and bottomed at -$254000.0 in Q4 2014.
- The 5-year median for Depreciation & Amortization (CF) is $30000.0 (2016), against an average of $29368.4.
- Peak annual rise in Depreciation & Amortization (CF) reached 11500.0% in 2014, while the deepest fall reached 315.25% in 2014.
- Tracing SLS's Depreciation & Amortization (CF) over 5 years: stood at $118000.0 in 2013, then plunged by 315.25% to -$254000.0 in 2014, then gained by 22.44% to -$197000.0 in 2015, then jumped by 53.3% to -$92000.0 in 2016, then soared by 127.17% to $25000.0 in 2017.
- Per Business Quant, the three latest SLS Depreciation & Amortization (CF) figures stand at $25000.0 (Q3 2017), $25000.0 (Q2 2017), and $26000.0 (Q1 2017).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 25,000.00 |
| Sep 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 25,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Dec 31, 2016 | -92,000.00 |
| Dec 31, 2016 | -92,000.00 |
| Sep 30, 2016 | 30,000.00 |
| Sep 30, 2016 | 30,000.00 |
| Jun 30, 2016 | 59,000.00 |
| Jun 30, 2016 | 59,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Dec 31, 2015 | -197,000.00 |
| Dec 31, 2015 | -197,000.00 |
| Sep 30, 2015 | 123,000.00 |
| Sep 30, 2015 | 123,000.00 |
| Jun 30, 2015 | 83,000.00 |
| Jun 30, 2015 | 83,000.00 |
| Mar 31, 2015 | 98,000.00 |
| Mar 31, 2015 | 98,000.00 |
| Dec 31, 2014 | -254,000.00 |
| Dec 31, 2014 | -254,000.00 |
| Sep 30, 2014 | -121,000.00 |
| Sep 30, 2014 | -121,000.00 |
| Jun 30, 2014 | 229,000.00 |
| Jun 30, 2014 | 229,000.00 |
| Mar 31, 2014 | 232,000.00 |
| Mar 31, 2014 | 232,000.00 |
| Dec 31, 2013 | 118,000.00 |
| Dec 31, 2013 | 118,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Jun 30, 2013 | 39,000.00 |
| Jun 30, 2013 | 39,000.00 |
| Mar 31, 2013 | 2,000.00 |
| Mar 31, 2013 | 2,000.00 |
| Dec 31, 2012 | 2,000.00 |
| Dec 31, 2012 | 2,000.00 |
| Sep 30, 2012 | 3,000.00 |
| Sep 30, 2012 | 3,000.00 |
| Jun 30, 2012 | 2,000.00 |
| Jun 30, 2012 | 2,000.00 |
| Mar 31, 2012 | 42,000.00 |
| Mar 31, 2012 | 42,000.00 |
| Dec 31, 2011 | 37,000.00 |
| Dec 31, 2011 | 37,000.00 |
| Sep 30, 2011 | 42,000.00 |
| Sep 30, 2011 | 42,000.00 |
| Jun 30, 2011 | 47,000.00 |
| Jun 30, 2011 | 47,000.00 |
| Mar 31, 2011 | 37,000.00 |
| Mar 31, 2011 | 37,000.00 |
| Dec 31, 2010 | 45,000.00 |
| Dec 31, 2010 | 45,000.00 |
| Sep 30, 2010 | 42,000.00 |
| Sep 30, 2010 | 42,000.00 |